Intrapleural BCG in postsurgical stage I non-small cell lung cancer

Anticancer Res. Mar-Apr 1989;9(2):391-3.

Abstract

In a randomized trial comparing intrapleural bacillus Calmette-Guérin (BCG) with placebo in postsurgical stage I non-small cell lung cancer, BCG-treated patients (n = 17) showed a non-significant overall improvement of 5-year and median survival and disease-free interval, but an increased rate of recurrence of cancer compared with control patients (n = 17).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Female
  • Humans
  • Immunotherapy
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Mycobacterium bovis / immunology*

Substances

  • Adjuvants, Immunologic